Lionheart Health, a regenerative health and longevity technology company, has formed a strategic partnership with Rejuvant, developer of patented Calcium alpha-ketoglutarate (CaAKG) supplementation, as part of Lionheart's participation in the XPRIZE Healthspan Semi-Finals. This collaboration positions Lionheart Health among the top 40 semi-finalists selected from more than 600 entries in spring 2025, highlighting the competitive nature of this global healthspan initiative.
The partnership designates Rejuvant's CaAKG supplement as a mandatory core component of both the Lionheart KLOTHO-UP™ Study and the broader Lionheart Klotho Wellness Program. These programs form the foundation of Lionheart's XPRIZE Healthspan initiative and incorporate peer-reviewed research demonstrating CaAKG's association with improvements in biological age markers. This integration represents a significant development in longevity research, combining validated nutritional interventions with advanced technological approaches.
The Lionheart KLOTHO-UP™ Study integrates Rejuvant's CaAKG supplementation within a multi-modal healthspan optimization framework designed to evaluate coordinated improvements across muscle, metabolic, immune, cardiovascular, and brain health domains. In addition to Rejuvant CaAKG, all study participants receive SNiP Nutrition™ personalized supplements customized based on genetic and biomarker profiles, targeted Klotho-focused supplementation, and Lionheart Health's BodStim™ bioelectric exercise platform. This platform delivers Klotho- and follistatin-elevating electrical muscle stimulation-enhanced exercise sessions lasting one hour, two to three times per week.
This comprehensive approach reflects Lionheart's belief that meaningful healthspan extension requires both lifestyle optimization and advanced biological technologies working in concert. The program's significance lies in its integrated methodology, which moves beyond single-intervention approaches to address multiple biological systems simultaneously. Participants can learn more about the program through the company's website at https://lionheartlongevity.com/treatment/klotho-wellness-program/.
All enrollees in the KLOTHO-UP™ Study and Klotho Wellness Program undergo extensive testing and evaluation at baseline, 3 months, 6 months, and 12 months. The protocol includes a 461-biomarker comprehensive blood panel including klotho levels, AI-enhanced full-body MRI with targeted organ and tissue analysis, muscle health assessments, gut health and microbiome evaluation, breathing and sleep analysis, stress and inflammation profiling, blood sugar and metabolic regulation analysis, vascular and calcification assessment, joint health and mobility evaluation, sexual health assessment, vision and hearing evaluation, and brain health testing including cognition, memory, and mood metrics.
This longitudinal design enables objective tracking of functional healthspan changes over time rather than reliance on single-endpoint or short-duration outcomes. The depth and breadth of these measurements represent a significant advancement in healthspan research methodology, providing more comprehensive data than traditional clinical trials. A Lionheart Health spokesperson noted that "Rejuvant's CaAKG platform represents one of the most rigorously studied nutritional interventions in the biological aging space" and that making it a mandatory core component anchors their program in validated metabolic biology while layering in advanced bioelectric, Klotho-focused, and personalized technologies.
A Rejuvant representative added that the collaboration allows CaAKG supplementation to be evaluated within "one of the most comprehensive, biomarker-driven healthspan programs ever assembled." This partnership matters because it represents a convergence of different longevity approaches—nutritional supplementation, personalized medicine, bioelectric stimulation, and comprehensive biomarker tracking—within a structured research framework. The implications extend beyond the XPRIZE competition, potentially establishing new standards for how healthspan interventions are developed, tested, and implemented across the longevity industry.
